Metamark Genetics, Inc. Seeks to Tell Docs When to Treat Prostate Cancer, and When Not
Xconomy -- Metamark Genetics has graduated from stealth mode. Now the Cambridge, MA-based startup, founded by top scientists at Harvard University and elsewhere, has hired a diagnostics industry veteran as its chief executive, and set a public goal for releasing a product that could change the way physicians decide how to treat prostate cancer in its early stages.